Clinical trials · Minneapolis–St. Paul, MN
Heart failure clinical trials in Minneapolis–St. Paul
We’re tracking 29 recruiting heart failure studies with a site in or near Minneapolis–St. Paul — including Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Minneapolis–St. Paul
- NCT06307652RecruitingPhase 3
Testing a new heart failure and kidney treatment combo
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
Minneapolis, MinnesotaAges 18–130 - NCT06310031Recruiting
Testing BrioVAD heart pump for severe heart failure
This trial tests a new left-ventricular assist device (LVAD) called BrioVAD for people with advanced heart failure who are not getting enough benefit from medicines. If you qualify, the device is implanted to help your heart pump blood.
Minneapolis, MinnesotaAges 18–100 - NCT06979362RecruitingPhase 2
Testing a new medicine for heart failure with thickened heart muscle
This study tests an experimental medicine, CDR132L, to see if it can improve heart structure and function in people with a type of heart failure where the heart muscle is thickened. If you have heart failure with normal pumping function and thickened heart walls, this trial may offer access to a new potential treatment.
Minneapolis, MinnesotaAges 40–84 - NCT06677060RecruitingPhase 3
Study of baxdrostat plus dapagliflozin for heart risk in type 2 diabetes
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
Minneapolis, MinnesotaAges 40 years+ - NCT06898515Recruiting
Fluid removal study for acute heart failure patients
This trial tests a device designed to safely remove extra fluid from patients hospitalized with worsening heart failure. It may help those who are not responding well to standard water pills (diuretics).
Minneapolis, MinnesotaAges 22 years+ - NCT06024746RecruitingPhase 3
Finerenone plus SGLT2i for hospitalized heart failure
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
Minneapolis, MinnesotaAges 18 years+ - NCT06008197RecruitingPhase 3
A study of finerenone for hospitalized heart failure patients
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
Minneapolis, MinnesotaAges 18 years+ - NCT06812533Recruiting
Testing a new approach for heart failure with weak pump
This study tests a new device or procedure to help people with heart failure and a weak heart pump. If you have a low ejection fraction and are on standard medications, you may be able to join.
Minneapolis, MinnesotaAges 18 years+ - NCT00271180Recruiting
Tracks long-term performance of Medtronic heart devices
This study follows how well certain Medtronic heart devices work over the long term. You may be included if you have a qualifying Medtronic implant and the research team can reliably get your implant and follow-up information.
Minneapolis, MinnesotaAges Any age - NCT07795814RecruitingPhase 2
Study of a new medicine for heart failure with preserved pumping function
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
Minneapolis, MinnesotaAges 30–84 - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Minneapolis, MinnesotaAges birth–20 years - NCT03523416Recruiting
Shunt device for heart failure with reduced pumping function
This trial studies a small device placed in the heart to create a passage that may help relieve pressure and improve symptoms in people with heart failure and a weak pumping function. It aims to see if the device is safe and helpful for daily life.
Minneapolis, MinnesotaAges 18 years+ - NCT06425848Recruiting
Heart failure monitoring study
This study looks at how a small monitor inside the blood vessel to the lungs helps manage heart failure. It aims to improve care for people with advanced heart failure.
Minneapolis, MinnesotaAges 18–100 - NCT06033950RecruitingPhase 3
A study of finerenone for heart failure patients who can't take standard MRA drugs
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
Minneapolis, MinnesotaAges 18 years+ - NCT05934487Recruiting
Monitoring device trial for stable heart failure symptoms
This trial tests whether a wearable home monitoring system (myCordella™) can help people with moderate heart failure (NYHA class II or III) by tracking heart pressure and supporting follow-up care. It may help detect changes earlier so clinicians can adjust treatment sooner.
Minneapolis, MinnesotaAges 18 years+ - NCT06935370RecruitingPhase 3
Testing vicadrostat with empagliflozin for heart failure with weak pump
This trial tests a new drug called vicadrostat combined with another drug, empagliflozin, for people with heart failure and a weak heart pump. It aims to see if this combination helps improve symptoms and outcomes.
Minneapolis, MinnesotaAges 18 years+ - NCT06678841Recruiting
Pacing therapy for heart failure with preserved pumping ability
This study tests a new pacing approach for people with a specific type of heart failure (HFpEF) to see if it can improve symptoms and quality of life. It involves a pacemaker-like device that adjusts heart rate based on your needs.
Minneapolis, MinnesotaAges 40 years+ - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Minneapolis, MinnesotaAges 18 years+ - NCT06424288RecruitingPhase 3
Testing vicadrostat plus empagliflozin for heart failure
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
Minneapolis, MinnesotaAges 18 years+ - NCT05064709Recruiting
Test device for heart failure symptoms in some patients
This study tests whether a heart-related device called CCM can improve symptoms and daily function in people with heart failure and a moderately reduced pumping strength. It may help if you’ve had recent heart-failure-related hospital care or urgent treatment and your heart and overall health fit the study limits.
Minneapolis, MinnesotaAges 18 years+ - NCT06360380Recruiting
Wearable device for fluid removal in heart failure
This trial tests a wearable device that removes extra fluid from your body without using the kidneys. It may help people with heart failure who still have fluid buildup despite taking high doses of water pills.
Minneapolis, MinnesotaAges 21–79 - NCT07037459RecruitingPhase 3
A study of a new drug for heart failure with obesity
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
Minneapolis, MinnesotaAges 18–99 - NCT05685303Recruiting
Testing a treatment for heart failure symptoms with normal pumping ability
This study is looking at a new treatment for people with heart failure where the heart’s pumping strength is not reduced much (HFpEF or HFmrEF), but pressure inside the heart is high during exercise. It may help relieve symptoms in people who still feel unwell during normal activity despite stable standard treatment.
Minneapolis, MinnesotaAges 40 years+ - NCT05996328Recruiting
Healthy meals for veterans with heart failure
This study tests whether providing healthy meals to veterans recently hospitalized for heart failure can improve their health and reduce the chance of going back to the hospital. Participants will receive meals at home for a period of time.
Minneapolis, MinnesotaAges 60 years+
Hear when a new Heart failure trial opens near Minneapolis–St. Paul, MN
We’ll email you when one opens near Minneapolis–St. Paul, MN — at most once a week, no account needed, unsubscribe anytime.
Heart failure trials in other cities
Where these studies are running near Minneapolis–St. Paul
Institutions with a site for the recruiting heart failure studies listed above.
- University of Minnesota · 6 studies
- Minneapolis Heart Institute Foundation · 3 studies
- Abbott-Northwestern Hospital · 2 studies
- Minneapolis VA Health Care System · 2 studies
- Research Site · 2 studies
- Fairview Health
- Fairview Health Services M Health Fairview St Johns Hospital
- Local Institution - 28
What taking part in a heart failure study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting heart failure studies in Minnesota.
Common questions
- Are there heart failure clinical trials near Minneapolis–St. Paul?
- Yes. We're currently tracking 29 recruiting heart failure studies with a site near Minneapolis–St. Paul, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a heart failure study near Minneapolis–St. Paul?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minneapolis–St. Paul to take part?
- Not necessarily. These studies have a site near Minneapolis–St. Paul, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a heart failure trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New heart failure studies open near Minneapolis–St. Paul regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.